Editorial. Pathophysiology of Type 2 Diabetes: The Long Journey into Present

Open access

1. DeFronzo RA. Lilly Lecture: the triumvirate: beta cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37: 667-687, 1988.

2. DeFronzo RA. Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795, 2009.

3. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378: 169-181, 2011.

4. Prentki M, Nolan CJ. Islet β cell failure in type 2 diabetes. J Clin Invest 116: 1802-1812, 2006.

5. Girard J. The inhibitory effects of insulin on hepatic glucose production are both direct and indirect. Diabetes 55 [Suppl. 2]: S65-S69, 2006.

6. Matsuda M, DeFronzo RA, Glass L et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51: 1111-1119, 2002.

7. Clore JN, Stillman J, Sugerman H. Glucose-6- phosphatase flux in vitro is increased in type 2 diabetes. Diabetes 49: 969-974, 2000.

8. Haeusler RA, Camastra S, Astiarraga B, Nannipieri M, Anselmino M, Ferrannini E. Decreased expression of hepatic glucokinase in type 2 diabetes. Mol Metab 18; 4: 222-226, 2014.

9. Gastaldelli A, Baldi S, Pettiti M et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49: 1367-1373, 2000.

10. Pendergrass M, Bertoldo A, Bonadonna R et al. Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals. Am J Physiol Endocrinol Metab 292: E92-100, 2007.

11. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53: 1270-1287, 2010.

12. Bajaj M, Defronzo RA. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 10: 311-323, 2003.

13. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 31: 364-395, 2010.

14. Abdul-Ghani M, Tripathy D, DeFronzo RA. Contribution of beta cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29: 1130-1139, 2006.

15. Huang CJ, Lin CY, Haataja L et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 56: 2016-2027, 2007.

16. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. In: International Textbook of Diabetes Mellitus, 4th edition. DeFronzo RA, Ferrannini E, Zimmet P, Alberti KGMM (eds). Wiley Blackwell, Chichester, pp 371-400, 2015.

17. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes 59: 1117-1125, 2010.

18. Bays HE, González-Campoy JM, Bray GA et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 6: 343-368, 2008.

19. Kashyap SR, Belfort R, Berria R et al. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab 287: E537-546, 2004.

20. Belfort R, Mandarino L, Kashyap S et al. Doseresponse effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54: 1640-1648, 2005.

21. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32: 515-531, 2011.

22. DeFronzo RA, Hompesch M, Kasichayanula S et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36: 3169-3176, 2013.

23. Plum L, Belgardt BF, Brüning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest 116: 1761-1766, 2006.

24. Kleinridders A, Cai W, Cappellucci L et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA 112: 3463-3468, 2015.

25. DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 34: 789-794, 2011.

26. Derghal A, Djelloul M, Airault C et al. Leptin is required for hypothalamic regulation of miRNAs targeting POMC 3'UTR. Front Cell Neurosci 9: 172, 2015.

27. DeFronzo RA, Triplitt CL, Abdul-Ghani M, Cersosimo E. Novel agents for the treatment of type 2 diabetes. Diabetes Spectr 27: 100-112, 2014.

28. Pinney SE, Simmons RA. Epigenetic mechanisms in the development of type 2 diabetes. Trends Endocrinol Metab 21: 223-229, 2010.

29. Chen H, Simar D, Morris MJ. Hypothalamic neuroendocrine circuitry is programmed by maternal obesity: interaction with postnatal nutritional environment. PloS One 4: e6259, 2009.

30. Yajnik CS, Deshpande SS, Jackson AA et al. Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the off spring: the Pune Maternal Nutrition Study. Diabetologia 51: 29-38, 2008.

31. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 1790: 671-681, 2009.

32. Barrett H, McElduff A. Vitamin D and pregnancy: an old problem revisited. Best Pract Res Clin Endocrinol Metab 24: 527-539, 2010.

33. Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 33: 2277-2284, 2010.

Romanian Journal of Diabetes Nutrition and Metabolic Diseases

The Journal of Romanian Society of Diabetes Nutrition and Metabolic Diseases

Journal Information

CiteScore 2017: 0.11

SCImago Journal Rank (SJR) 2017: 0.122
Source Normalized Impact per Paper (SNIP) 2017: 0.077


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 250 250 44
PDF Downloads 164 164 36